Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXEL: Axitinib and Avelumab in Recurrent or Metastatic Nasopharyngeal Cancer
NCT04562441Phase 2Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- May 2021
- Primary completion
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axitinib and avelumab in nasopharyngeal carcinoma (NPC), sponsored by The Chinese University of Hong Kong. Primary endpoint: Confirmed Objective Response Rate at 2 years. Started May 2021; status: completed.
02
Drugs
axitinibavelumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04562441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04562441.